Institutional Research Archive

Hedge Fund Letters Archive

Browse the world's most comprehensive database of hedge fund investor letters, sorted by recent quarter. Access primary source research from leading institutional managers.

Quarter	Letter Date	Fund Name	QTD	YTD	Tickers	Themes	Quick Take

Home Letters Funds Account

Carillon Eagle Small Cap Growth Fund 2024 Q2 Investor Letter | Buyside Digest

Back to Fund Profile (Carillon Eagle Small Cap Growth Fund)

Primary Source Intelligence • Q2 2024 Letter Analysis

Carillon Eagle Small Cap Growth Fund Quarterly Analysis

Buyside Digest is not affiliated with, and does not endorse, Carillon Eagle Small Cap Growth Fund. This analysis is provided for institutional research purposes only and is not investment advice.

Fund Returns

Annualized+1.41%

Positioning StanceNEUTRAL

Digest Analysis

Quick Take

"Small-cap growth fund focused on companies with strong balance sheets and secular growth exposure. Key themes include AI data center buildout, healthcare innovation including GLP-1 drugs, and disciplined energy companies."

Executive Summary

The Carillon Eagle Small Cap Growth Fund targets small-cap growth companies with strong fundamentals and secular growth drivers. The fund's core thesis centers on investing in companies with pristine balance sheets and durable business models that generate significant free cash flows over economic cycles. Key portfolio themes include AI data center buildout, where holdings benefit from surge in capital spending by mega-cap tech companies on electrical equipment and power generation. Healthcare represents another major focus, with exposure to GLP-1 obesity drugs, contract research organizations, and companies with disruptive medical technologies. The fund also maintains positions in energy companies with disciplined capital allocation focused on shareholder returns. Top performers included Insmed, TransMedics, and Abercrombie & Fitch, while Summit Materials and Viking Therapeutics faced headwinds. The managers maintain a constructive outlook on equity markets given easing inflation and reasonable valuations, though they acknowledge risks from Fed hawkishness and potential policy mistakes. The portfolio remains positioned for secular growth themes while emphasizing quality fundamentals.

Unlock Full Institutional Analysis

Sign in or create a free account to unlock full commentary, extracted equity pitches, and direct outbound manager source links with your 3 quarterly credits.

Sign In to Unlock (3 Free Credits)View Pricing Tiers

Institutional Meta Strategy

Meta Strategy Gauges

Algorithmic conviction, macroeconomic posture, and risk appetite signals extracted from this quarterly letter with qualitative explanations.

Signal Matrix

Market Conviction

68%

CautiousHigh

Moderate (68%)

The fund demonstrates moderate-high conviction through its 99-position portfolio with clear thesis articulation for individual holdings and specific sector themes. Named positions like Insmed, TransMedics, and Onto Innovation receive detailed analysis with specific catalysts and market dynamics. The managers express strong conviction in secular themes like AI data centers and healthcare innovation, though the diversified nature of the portfolio prevents an extremely high score.

Growth Outlook

25%

BearishBullish

Bearish (25%)

The managers express a constructive outlook for equity markets citing easing inflation and reasonable valuations, but this optimism is tempered by significant concerns about Fed hawkishness and policy mistake risks. The balanced tone with both positive and negative factors results in a mildly positive but cautious sentiment.

Risk Appetite

15%

DefensiveAggressive

Defensive (15%)

The fund maintains exposure to growth themes like AI and healthcare but emphasizes companies with pristine balance sheets and strong fundamentals, suggesting a selective risk-on approach. The focus on quality and cash flow generation indicates measured risk appetite rather than aggressive positioning.

Capital Deployment

5%

De-riskingDeploying

De-risking (5%)

The letter mentions adding several new healthcare companies with disruptive technologies but provides no specific cash level changes or broad deployment activity. The addition of new positions suggests modest net deployment, but without cash percentage data or broader portfolio changes, the activity appears limited to rotation and selective additions.

Forward Guidance

10%

CautiousExpansionary

Cautious (10%)

The managers indicate they remain committed to their investment approach and see opportunities in secular themes, but there's no explicit discussion of aggressive deployment or major portfolio changes. The guidance suggests steady execution rather than bold directional moves.

Language Signal

20%

BearishBullish

Bearish (20%)

The letter contains more opportunity-focused language around AI, healthcare innovation, and attractive valuations than risk language, though Fed policy concerns and economic headwinds are meaningfully discussed. The net balance tilts slightly toward constructive language.

Perceived Risk

65%

Low RiskElevated

Elevated Risk (65%)

The managers identify multiple specific risks including Fed policy mistakes, employment data softening, housing market challenges, OPEC supply discipline concerns, and weather impacts on construction. These risks receive meaningful discussion with concrete examples and potential impacts, indicating moderate-high perceived risk in the environment.

Opportunity Density

70%

ScarceAbundant

Abundant (70%)

The managers see selective opportunities across multiple themes including AI data centers, healthcare innovation, and energy companies with disciplined capital allocation. They specifically mention finding attractive opportunities in technology, healthcare, and consumer sectors, suggesting a reasonably rich but selective opportunity set requiring careful stock selection.

Time Horizon

65%

Short-TermLong-Term

Multi-Year (65%)

The fund focuses on companies with durable business models that generate cash flows over economic cycles, suggesting a multi-year investment horizon. The emphasis on secular themes like AI data centers and healthcare innovation implies 2-3 year thesis timeframes, though some positions like TransMedics and Insmed appear to have nearer-term catalysts around product approvals and market adoption.